Fujian Cancer Hospital: all 162 studies
Page 2 of 2. Open to participants first (92), then studies with results posted, then the rest; newest registration first within each.
- Almonertinib Plus Metronomic Oral VinorelbineStatus unknownNCT05663177
- Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer PainStatus unknownNCT05561023Phase 1
- the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug ChemotherapyStatus unknownNCT05497076
- To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon CancerStatus unknownNCT05335460Phase 2
- TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal CancerStatus unknownNCT05314101Phase 2
- Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal CancerStatus unknownNCT05266820Phase 2
- Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerCompletedNCT05223088Phase 2
- Tislelizumab as Cross-line Treatment for Advanced NSCLCStatus unknownNCT05192681Phase 2
- the Role of ctDNA in Predicting the Recurrence Risk of Colorectal CancerStatus unknownNCT05131243Not applicable
- Effects of Mobile Medicine on Cancer PatientsStatus unknownNCT05049811Not applicable
- Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric CancerStatus unknownNCT05035446Phase 3
- PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT05007145Phase 2
- Study of FMT Combined With Nivolumab in Gastric CancerWithdrawnNCT05001360Not applicable
- Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04955886Phase 2
- Using Mini Program for Self-management VS Conventional Pharmaceutical Care for Cancer PainStatus unknownNCT04844645Not applicable
- IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful TitrationCompletedNCT04785768Phase 3
- Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II StudyStatus unknownNCT04764006Phase 2
- Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPCStatus unknownNCT04745741
- Second-line Surufatinib Combined With Chemotherapy in Advanced CRCStatus unknownNCT04734249Phase 2
- Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line ChemotherapyStatus unknownNCT04613804Phase 2
- Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer PainStatus unknownNCT04533243Phase 3
- Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPCStatus unknownNCT04421469Phase 2
- To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPCCompletedNCT04387266
- Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell CarcinomaStatus unknownNCT04354961Phase 2
- Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal CarcinomaStatus unknownNCT04319471Phase 2
- Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful TitrationCompletedNCT04243954Phase 2
- Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPCStatus unknownNCT04220528Phase 2
- PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric CancerStatus unknownNCT04174339Not applicable
- POF Versus FOLFOX Plus IP Paclitaxel in AGCStatus unknownNCT04155671Phase 2
- Neoadjuvant POF in the Treatment of Locally Advanced Gastric CancerStatus unknownNCT04149015Phase 2
- Study of the Apatinib Combine With POF Versus POF in Gastric CancerStatus unknownNCT04121039Phase 2
- Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy RegimensStatus unknownNCT04089657Phase 2
- Effects of Anesthesia on Tumor Immunity and Insulin Resistance During Perioperative PeriodCompletedNCT03872635Not applicable
- A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric CancerStatus unknownNCT03788226Phase 3
- Apatinib Combined With POF for Second-line Treatment of Gastric AdenocarcinomaStatus unknownNCT03788174Phase 2
- EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLCStatus unknownNCT03720873Phase 2
- Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal AdenocarcinomaWithdrawnNCT03708536Phase 3
- Study of the Combination of Apatinib and POFStatus unknownNCT03707639Phase 2
- Nimotuzumab for Recurrent Nasopharyngeal CarcinomaStatus unknownNCT03666221Phase 2
- EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPCStatus unknownNCT03648697Phase 2
- Cognitive Dysfunction in Patients With Cancer PainStatus unknownNCT03641820
- Change the Dose Frequency of Controlled-Release Oxycodone to Refractory PainWithdrawnNCT03639415Phase 4
- Phase I Study of the Combination of Anlotinib With Pemetrexed or DocetaxelStatus unknownNCT03566576Not applicable
- Appaconitine Patch for Oral Mucositis Pain Caused by Chemoradiotherapy in Patients With Nasopharyngeal CancerStatus unknownNCT03518489Not applicable
- Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell CarcinomaStatus unknownNCT03486509Phase 2
- Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR MutationStatus unknownNCT03486496Phase 2
- Next-generation Sequencing in Gastrointestinal CancerStatus unknownNCT03476057
- Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal CancerWithdrawnNCT03380689Phase 1
- PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer PainCompletedNCT03375515Phase 3
- EGFR Mutation Positive NSCLC Patients With Gefitinib and ThalidomideStatus unknownNCT03341494Phase 2
- Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess TreatmentStatus unknownNCT03244904
- Phase I Study of the Combination of Apatinib and POFStatus unknownNCT03244774Phase 1
- Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRCWithdrawnNCT03222089Phase 2
- Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric CancerStatus unknownNCT03137004Phase 2
- mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJAStatus unknownNCT03045770Not applicable
- Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJAStatus unknownNCT03030937Phase 2
- EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLCStatus unknownNCT02886195Phase 3
- The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC PatientsStatus unknownNCT02865304Phase 3
- POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGCCompletedNCT02845908Phase 2
- Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric CancerStatus unknownNCT02697838Phase 2
- Comparison of Short Term Outcomes Between Totally Laparoscopic and Laparoscopy-Assisted Distal Gastrectomy With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric CancerStatus unknownNCT02365896Not applicable
- Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal CarcinomaCompletedNCT02113423Not applicable